PRC-063

DRUG2 trials

Sponsors

Rhodes Pharmaceuticals, L.P.

Conditions

ADHDAttention Deficit Hyperactivity Disorder

Phase 3

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

CompletedNCT02168127

Rhodes Pharmaceuticals, L.P.ADHD

Start: 2014-05-31End: 2015-06-30Updated: 2015-07-08

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

CompletedNCT02555150

Rhodes Pharmaceuticals, L.P.Attention Deficit Hyperactivity Disorder

Start: 2015-09-30End: 2017-01-31Target: 40Updated: 2017-01-19

Related Papers

Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up

Journal of Child and Adolescent Psychopharmacology2021-10-298 citations

Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension

Journal of Child and Adolescent Psychopharmacology2021-10-1210 citations

Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.

2021-05-316 citations